BlackRock Inc. Sells 278,114 Shares of Becton Dickinson and Co (NYSE:BDX)

BlackRock Inc. trimmed its stake in shares of Becton Dickinson and Co (NYSE:BDX) by 1.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 18,933,224 shares of the medical instruments supplier’s stock after selling 278,114 shares during the quarter. BlackRock Inc. owned approximately 7.01% of Becton Dickinson and worth $4,771,361,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently bought and sold shares of the company. Comerica Securities Inc. raised its stake in Becton Dickinson and by 31.2% in the fourth quarter. Comerica Securities Inc. now owns 2,742 shares of the medical instruments supplier’s stock valued at $618,000 after purchasing an additional 652 shares in the last quarter. Geode Capital Management LLC raised its stake in Becton Dickinson and by 7.5% in the fourth quarter. Geode Capital Management LLC now owns 3,208,583 shares of the medical instruments supplier’s stock valued at $721,582,000 after purchasing an additional 223,215 shares in the last quarter. InterOcean Capital LLC acquired a new position in Becton Dickinson and in the first quarter valued at about $204,000. Robeco Institutional Asset Management B.V. raised its stake in Becton Dickinson and by 1.9% in the first quarter. Robeco Institutional Asset Management B.V. now owns 10,973 shares of the medical instruments supplier’s stock valued at $2,740,000 after purchasing an additional 200 shares in the last quarter. Finally, Cornerstone Advisors Inc. raised its stake in Becton Dickinson and by 19.0% in the first quarter. Cornerstone Advisors Inc. now owns 571 shares of the medical instruments supplier’s stock valued at $143,000 after purchasing an additional 91 shares in the last quarter. Institutional investors and hedge funds own 84.26% of the company’s stock.

A number of research firms recently commented on BDX. Piper Jaffray Companies dropped their price target on Becton Dickinson and from $267.00 to $266.00 and set an “overweight” rating for the company in a research note on Tuesday, August 6th. Zacks Investment Research raised Becton Dickinson and from a “sell” rating to a “hold” rating in a research note on Monday, May 20th. ValuEngine downgraded Becton Dickinson and from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Raymond James boosted their price target on Becton Dickinson and from $265.00 to $288.00 and gave the company a “strong-buy” rating in a research note on Friday, June 28th. Finally, Wells Fargo & Co boosted their price target on Becton Dickinson and from $270.00 to $290.00 and gave the company an “outperform” rating in a research note on Friday, September 6th. Five equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $266.55.

Becton Dickinson and stock opened at $262.15 on Friday. Becton Dickinson and Co has a 12-month low of $208.62 and a 12-month high of $265.87. The company has a quick ratio of 0.67, a current ratio of 1.09 and a debt-to-equity ratio of 0.84. The business’s 50-day moving average price is $252.38 and its two-hundred day moving average price is $245.32. The stock has a market cap of $70.33 billion, a PE ratio of 23.81, a P/E/G ratio of 1.89 and a beta of 1.13.

Becton Dickinson and (NYSE:BDX) last released its quarterly earnings results on Tuesday, August 6th. The medical instruments supplier reported $3.08 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.05 by $0.03. The company had revenue of $4.35 billion for the quarter, compared to analysts’ expectations of $4.37 billion. Becton Dickinson and had a return on equity of 14.78% and a net margin of 5.02%. The business’s quarterly revenue was up 1.7% compared to the same quarter last year. During the same period in the previous year, the business posted $2.91 earnings per share. As a group, analysts expect that Becton Dickinson and Co will post 11.68 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Monday, September 30th. Stockholders of record on Monday, September 9th will be issued a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a dividend yield of 1.17%. The ex-dividend date is Friday, September 6th. Becton Dickinson and’s dividend payout ratio (DPR) is currently 27.97%.

In other news, CEO Vincent A. Forlenza sold 11,532 shares of the business’s stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $260.38, for a total transaction of $3,002,702.16. Following the sale, the chief executive officer now directly owns 218,671 shares in the company, valued at $56,937,554.98. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Claire Fraser sold 1,429 shares of the business’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $243.26, for a total value of $347,618.54. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 37,249 shares of company stock worth $9,616,803. Company insiders own 0.12% of the company’s stock.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Featured Story: Why is the conference call important?

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News